Article

Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management

University of Texas at San Antonio, San Antonio, Texas, United States
Archives of Internal Medicine (Impact Factor: 13.25). 04/2007; 167(6):551-61. DOI: 10.1001/archinte.167.6.551
Source: PubMed

ABSTRACT Implementation of the chronic care model (CCM) has been shown to be an effective preventative strategy to improve outcomes in diabetes mellitus, depression, and congestive heart failure, but data are lacking regarding the effectiveness of this model in preventing complications in patients with chronic obstructive pulmonary disease.
We searched the MEDLINE, CINAHL, and Cochrane databases from inception to August 2005 and included English-language articles that enrolled adults with chronic obstructive pulmonary disease and (1) contained intervention(s) with CCM component(s), (2) included a comparison group or measures at 2 points (before/after), and (3) had relevant outcomes. Two reviewers independently extracted data.
Symptoms, quality of life, lung function, and functional status were not significantly different between the intervention and control groups. However, pooled relative risks (95% confidence intervals) for emergency/unscheduled visits and hospitalizations for the group that received at least 2 CCM components were 0.58 (0.42-0.79) and 0.78 (0.66-0.94), respectively. The weighted mean difference (95% confidence interval) for hospital stay was -2.51 (-3.40 to -1.61) days shorter for the group that received 2 or more components. There were no significant differences for those receiving only 1 CCM component.
Limited published data exist evaluating the efficacy of CCM components in chronic obstructive pulmonary disease management. However, pooled data demonstrated that patients with chronic obstructive pulmonary disease who received interventions with 2 or more CCM components had lower rates of hospitalizations and emergency/unscheduled visits and a shorter length of stay compared with control groups. The results of this review highlight the need for well-designed trials in this population.

1 Bookmark
 · 
239 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of older and oldest old patients with COPD poses several problems and should be tailored to specific outcomes, such as physical functioning. Indeed, impaired homeostatic mechanisms, deteriorated physiological systems, and limited functional reserve mainly contribute to this complex scenario. Therefore, we reviewed the main difficulties in managing therapy for these patients and possible remedies. Inhaled long acting beta-agonists (LABA) and anticholinergics (LAMA) are the mainstay of therapy in stable COPD, but it should be considered that pharmacological response and safety profile may vary significantly in older patients with multimorbidity. Their association with inhaled corticosteroids is recommended only for patients with severe or very severe airflow limitation or with frequent exacerbations despite bronchodilator treatment. In hypoxemic patients, long-term oxygen therapy (LTOT) may improve not only general comfort and exercise tolerance, but also cognitive functions and sleep. Non-pharmacological interventions, including education, physical exercise, nutritional support, pulmonary rehabilitation and telemonitoring can importantly contribute to improve outcomes. Older patients with COPD should be systematically evaluated for the presence of risk factors for non-adherence, and the inhaler device should be chosen very carefully. Comorbidities, such as cardiovascular diseases, chronic kidney disease, osteoporosis, obesity, cognitive, visual and auditory impairment, may significantly affect treatment choices and should be scrutinized. Palliative care is of paramount importance in end-stage COPD. Finally, treatment of COPD exacerbations has been also reviewed. Therapeutic decisions should be founded on a careful assessment of cognitive and functional status, comorbidity, polypharmacy, and age-related changes in pharmacokinetics and pharmacodynamics in order to minimize adverse drug events, drug-drug or drug-disease interactions, and non-adherence to treatment.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) is one of the main causes of morbidity and mortality globally. In Trondheim in 2008 an integrated care model (COPD-Home) consisting of an education program, self-management plan, home visits and a call centre for patient support and communication was developed. The objective was to determine the efficacy of an intervention according to the COPD-Home model in reducing hospital utilization among patients with COPD stage III and IV (GOLD 2007) discharged after hospitalization for acute exacerbations of COPD (AECOPD).MethodsA single centre, prospective, open, controlled clinical study comparing COPD-Home integrated care (IC) with usual care (UC).ResultsNinety-one versus 81 patients mean age 73.4 ± 9.3 years (57% women) were included in the IC group (ICG) and the UC group (UCG) respectively, and after 2 years 51 and 49 patients were available for control in the respective groups. During the year prior to study start there were 71 hospital admissions (HA) in the ICG and 84 in the UCG. There was a 12.6% reduction in HA in the ICG during the first year of follow-up and a 46.5% reduction during the second year (p = 0.01) compared to an 8.3% increase during the first year and no change during the second year in the ICG. During the year prior to study start, the number of hospital days (HD) was 468 in the ICG and 479 in the UCG. In the IC group, the number of HD was reduced by 48.3% during the first year (p = 0.01), and remained low during the second year of follow-up (p=0.02). In the UC group, the number of HD remained unchanged during the follow-up period. There was a trend towards a shorter survival time among patients in the ICG compared to the UCG, hazard ratio 1.33 [95% CI 0.77 to 2.33].Conclusion Intervention according to the COPD-Home model reduced hospital utilization in patients with COPD III and IV with a persisting effect throughout the 2 years of follow-up. However, there was a trend towards a shorter survival time in the intervention group.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To assess symptoms of anxiety and depression among Portuguese patients with chronic obstructive pulmonary disease (COPD) and associated predictive factors. Study design: A multicentre, cross-sectional study. Setting: Three primary care centres and one district hospital in the central region of Portugal. Participants: 302 Portuguese outpatients with COPD. Methods: Symptoms of anxiety and depression were assessed with the Hospital Anxiety and Depression Scale (HADS). Scores ≥8 were considered clinically significant. Results: This sample of patients had a mean age of 67±12 years and 41% were female. COPD was graded as mild in 106 (35.1%), moderate in 106 (35.1%) and severe-to-very-severe 90 patients (29.8%). Clinically significant anxiety was found in 53.3% of patients and symptoms of depression in 45.4%. Symptoms of anxiety were associated with limitation of activities (OR 1.39, 95% CI 1.04-1.84), age (0.97, 95% CI 0.94-0.99) and female gender (OR 0.37; 95% CI 0.20-0.66). Symptoms of depression were associated with functional mobility (OR 1.91, 95% CI 1.38-2.66) and limitation of activities (OR 1.12, 95% CI 1.04-1.21). Conclusions: A high proportion of Portuguese patients with COPD experience symptoms of anxiety and depression. National pulmonary rehabilitation programmes might need to include collaborative self-management interventions to address patients’ emotional needs.

Full-text (2 Sources)

Download
141 Downloads
Available from
May 20, 2014